5-氯-2-羟基-3-甲基苯甲醛 | 23602-63-3

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-氯-2-羟基-3-甲基苯甲醛
• 中文别名: 3-甲基-5-氯水杨醛；5-氯-3-甲基-2-羟基苯甲醛
• 英文名称: 5-chloro-3-methylsalicylaldehyde
• 英文别名: 2-hydroxy-3-methyl-5-chlorobezaldehyde；5-chloro-2-hydroxy-3-methylbenzaldehyde；3-Methyl-5-chlor-salicylaldehyd；2-hydroxy-3-methyl-5-chlorobenzaldehyde；3-methyl-5-chloro-2-hydroxybenzaldehyde；5-chloro-3-methyl-2-hydroxybenzaldehyde
• CAS: 23602-63-3
• 化学式: C₈H₇ClO₂
• mdl: MFCD00275687
• 分子量: 170.595
• InChiKey: NSKZAOKQZDLHGO-UHFFFAOYSA-N

物化性质

• 熔点：
  67 °C
• 沸点：
  244.7±35.0 °C(Predicted)
• 密度：
  1.335±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。请避免接触氧化物和空气。

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2913000090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  在干性保护气体中处理，并确保贮藏容器密封。将容器存放在阴凉、干燥处。

SDS

Name:	5-Chloro-2-hydroxy-3-methylbenzaldehyde 95+% Material Safety Data Sheet
Synonym:
CAS:	23602-63-3

Section 1 - Chemical Product MSDS Name:5-Chloro-2-hydroxy-3-methylbenzaldehyde 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
23602-63-3	5-Chloro-2-hydroxy-3-methylbenzaldehyd	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Air sensitive.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 23602-63-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 69 - 70 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7ClO2
Molecular Weight: 171

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, moisture, exposure to air, contact with water.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 23602-63-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Chloro-2-hydroxy-3-methylbenzaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 23602-63-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 23602-63-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 23602-63-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-2-羟基-3-甲基苯甲醛 在 potassium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 5-Chloro-7-methyl-benzofuran-2-carbaldehyde
  参考文献：
  名称：

  3-Benzo[b]furyl- and 3-benzo[b]thienylaminobutyric acids as GABAB ligands. Synthesis and structure-activity relationship studies

  摘要：

  Baclofen (beta-p-chlorophenyl GABA) is one of the selective agonists for the bicuculline-insensitive GABA(B) receptors. In the search for new compounds that bind to GABA(B) receptors it is very important to clarify the structural requirements. We report the syntheses of and binding studies on various S-heteroaromatic (benzo[b]furan and benzo[b]thiophen)aminobutyric acids. The 4-amino-3-(7-methyl-benzo[b]furan-2-yl)butanoic acid 8g is a potent and specific ligand for GABA(B) receptors, with an IC50 value of 5.4 mu M in the displacement of [H-3]GABA.

  DOI：

  10.1016/0223-5234(96)85165-8
• 作为产物：
  描述：

  2-甲基苯甲醚 在 N-氯代丁二酰亚胺 、 三溴化硼 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 5-氯-2-羟基-3-甲基苯甲醛
  参考文献：
  名称：

  氘代苯并吡喃衍生物的合成作为具有改善的药代动力学性质的选择性COX-2抑制剂。

  摘要：

  我们设计了一系列专门氘化的苯并吡喃类似物作为新的COX-2抑制剂，旨在改善其药代动力学特性。如预期的那样，氘代化合物保留了对COX-2的效力和选择性。与它们的非氘代同类物相比，新分子在大鼠中具有改善的药代动力学特征。最重要的是，新化合物在几种小鼠炎症和疼痛模型中均显示出药效学功效。苯并吡喃衍生物被分离成它们的对映异构体，并且发现该活性与S-异构体有关。为了简化所需S异构体的合成，开发了有机催化的不对称多米诺oxa-Michael /羟醛缩合反应用于制备。

  DOI：

  10.1021/ml500299q

文献信息

• Propylphosphonic Anhydride (T3P®): A Remarkably Efficient Reagent for the One-Pot Transformation of Aromatic, Heteroaromatic, and Aliphatic Aldehydes to Nitriles
  作者：John Augustine、Rajendra Atta、Balakrishna Ramappa、Chandrakantha Boodappa

  DOI：10.1055/s-0029-1218388

  日期：2009.12

  Propylphosphonic anhydride has been demonstrated to be an efficient reagent for the transformation of aromatic, heteroaromatic, and aliphatic aldehydes to respective nitriles in excellent yields. This procedure offers simple and one-pot access to nitriles and highlights the synthetic utility of T3P® as a versatile reagent in organic chemistry.

  三丙基膦酐已被证明是一种高效的试剂，可将芳香族、杂芳香族和脂肪族醛分别转化为相应的腈，产率极佳。这一过程提供了简单且一步制备腈的方法，并强调了T3P®作为一种多功能试剂在有机化学中的合成应用价值。
• Zinc and enolato-magnesium complexes based on bi-, tri- and tetradentate aminophenolate ligands
  作者：Zhanjiang Zheng、Gang Zhao、Rémy Fablet、Miloud Bouyahyi、Christophe M. Thomas、Thierry Roisnel、Osvaldo Casagrande Jr、Jean-François Carpentier

  DOI：10.1039/b812754a

  日期：——

  The coordination chemistry of a series of potentially tetra-, tri- and bi-dentate aminophenol pro-ligands ([L1]H–[L5]H) with magnesium and zinc derivatives has been studied. Reactions of the pro-ligands [L1]H, [L2]H and [L3]H with one equiv. of ZnEt2 or Zn(N(SiMe3)2)2 in toluene at room temperature afford cleanly, viaethane or amine elimination, the ethyl- and amido-zinc complexes 1–4. Complexes [L4]ZnEt (5) and [L4]Zn(N(SiMe3)2)2 (6) derived from the tridentate pro-ligand [L4]H were prepared in 84% and 76% yields, following similar alkane and amine elimination protocols, respectively. The 1 : 1 reactions of bidentate pro-ligand [L5]H with ZnEt2 or Zn(N(SiMe3)2)2 in toluene using different reaction protocols systematically yielded mixtures of the bis(ligand) complex [L5]2Zn (7) and the corresponding ethyl-[L5]ZnEt}n (8; n = 1 or 2) or amido- [L5]Zn(N(SiMe3)2)}n complexes (9; n = 1 or 2). The synthesis of magnesium-enolate complexes 10 and 11 was carried out in a one-pot, two-step procedure by first reacting pro-ligands [L1]H and [L4]H with one equiv. of Mg(n,sBu)2 to generate the corresponding [Ln]Mg(n,sBu)}n species, which were further reacted with one equiv. of 2,4,6-Me3C6H2COMe. All complexes have been characterized by multinuclear NMR, elemental analysis, and by single-crystal X-ray diffraction studies for five-coordinate magnesium complex 10, and four-coordinate Zn complexes 3–7. Preliminary studies indicate that magnesium species 10 and 11 as well as zinc complexes 1 and 5 are not active initiators for the polymerization of methyl methacrylate, even in combination with one equiv. of Li[OC(CH2)(2,4,6-Me3C6H2)], while zinc complexes 2, 4 and 6 are effective initiators for the ring-opening polymerization of ε-caprolactone and rac-lactide at 20 °C.

  一系列潜在的四齿、三齿和二齿氨基酚前配体([L1]H–[L5]H)与镁和锌衍生物的配位化学已被研究。前配体[L1]H、[L2]H和[L3]H与等量的ZnEt2或Zn(N(SiMe3)2)2在室温下在甲苯中反应，通过乙烷或胺消除，干净地得到乙基和酰胺基锌配合物1–4。从三齿前配体[L4]H衍生的配合物[L4]ZnEt(5)和[L4]Zn(N(SiMe3)2)2(6)分别通过类似的烷烃和胺消除协议，以84%和76%的产率制备。二齿前配体[L5]H与ZnEt2或Zn(N(SiMe3)2)2在甲苯中的1:1反应，采用不同的反应协议，系统地生成了双(配体)配合物[L5]2Zn(7)和相应的乙基-[L5]ZnEt}n(8; n = 1或2)或酰胺- [L5]Zn(N(SiMe3)2)}n配合物(9; n = 1或2)的混合物。镁醇盐配合物10和11的合成采用了一锅法两步程序，首先将前配体[L1]H和[L4]H与等量的Mg(n,sBu)2反应生成相应的[Ln]Mg(n,sBu)}n物种，然后进一步与等量的2,4,6-Me3C6H2COMe反应。所有配合物均通过多核NMR、元素分析以及五配位镁配合物10和四配位锌配合物3–6的单晶X射线衍射研究进行了表征。初步研究表明，镁物种10和11以及锌配合物1和5即使与等量的Li[OC(CH2)(2,4,6-Me3C6H2)]结合，也不是甲基丙烯酸甲酯聚合的有效引发剂，而锌配合物2, 4和6在20°C下对于ε-己内酯和rac-乳酸的环开聚合是有效的引发剂。
• [EN] THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] ISOMERE R DE COMPOSES D'ACIDES AMINES BETA EN TANT QUE DERIVES ANTAGONISTES DU RECEPTEUR DES INTEGRINES
  申请人：PHARMACIA CORPRATION

  公开号：WO2004060376A1

  公开（公告）日：2004-07-22

  The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the αV β5 integrin without significantly inhibiting the αV β6 integrin

  本发明涉及一类由公式(I)表示的化合物或其药用可接受的盐，包含公式(I)化合物的药物组合物，以及在不显著抑制αVβ6整合素的情况下选择性抑制或拮抗αVβ3和/或αVβ5整合素的方法。
• INHIBITORS OF STEAROYL-COA DESATURASE
  申请人：Gillespie Paul

  公开号：US20090149466A1

  公开（公告）日：2009-06-11

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

  提供以下式(I)化合物： 以及药用可接受的盐，其中取代基如说明书中所披露。这些化合物以及包含它们的药物组合物可用于治疗诸如肥胖等疾病。
• [EN] TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS<br/>[FR] TRIAZOLONES UTILISÉES COMME INHIBITEURS D'ACIDES GRAS SYNTHASE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011103546A1

  公开（公告）日：2011-08-25

  This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

  这项发明涉及三唑酮衍生物在调节脂肪酸合成酶（FAS）的活性或功能，特别是抑制其活性或功能方面的用途。适当地，本发明涉及三唑酮在癌症治疗中的应用。